Overall, our findings indicate that in ROS1-positive NSCLC patients treated with crizotinib, those with positive PD-L1 expression experienced shorter PFS compared to patients with negative PD-L1 expression. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.